{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:57:38Z","timestamp":1766023058949,"version":"3.48.0"},"reference-count":33,"publisher":"e-Century Publishing Corporation","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Dis"],"DOI":"10.62347\/syix9692","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T22:12:12Z","timestamp":1713996732000},"page":"21-28","source":"Crossref","is-referenced-by-count":2,"title":["Retrospective study on the short-term efficacy of different doses of Spironolactone in patients with heart failure of ischemic cardiomyopath and the influence of ventricular remodeling markers"],"prefix":"10.62347","volume":"14","author":[{"given":"Li","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s11886-022-01766-6","article-title":"Ischemic cardiomyopathy and heart failure after acute myocardial infarction","volume":"24","author":"Del Buono","year":"2022","unstructured":"Del Buono MG, Moroni F, Montone RA, Azzalini L, Sanna T and Abbate A. Ischemic cardiomyopathy and heart failure after acute myocardial infarction. Curr Cardiol Rep 2022; 24: 1505-1515.","journal-title":"Curr Cardiol Rep"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s10741-010-9218-y","article-title":"Role of multimodality imaging in ischemic and non-ischemic cardiomyopathy","volume":"16","author":"Ananthasubramaniam","year":"2011","unstructured":"Ananthasubramaniam K, Dhar R and Cavalcante JL. Role of multimodality imaging in ischemic and non-ischemic cardiomyopathy. Heart Fail Rev 2011; 16: 351-67.","journal-title":"Heart Fail Rev"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/heartjnl-2017-311684","article-title":"Cochrane corner: stem cell therapy for chronic ischaemic heart disease and congestive heart failure","volume":"104","author":"Fisher","year":"2018","unstructured":"Fisher SA, Doree C, Mathur A, Taggart DP and Martin-Rendon E. Cochrane corner: stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Heart 2018; 104: 8-10.","journal-title":"Heart"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"991","DOI":"10.2165\/00002512-200724120-00003","article-title":"Drug treatment of chronic heart failure in the elderly","volume":"24","author":"Leibundgut","year":"2007","unstructured":"Leibundgut G, Pfisterer M and Brunner-La Rocca HP. Drug treatment of chronic heart failure in the elderly. Drugs Aging 2007; 24: 991-1006.","journal-title":"Drugs Aging"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3238\/arztebl.2020.0376","article-title":"The treatment of heart failure with reduced ejection fraction","volume":"117","author":"Berliner","year":"2020","unstructured":"Berliner D, Hänselmann A and Bauersachs J. The treatment of heart failure with reduced ejection fraction. Dtsch Arztebl Int 2020; 117: 376-386.","journal-title":"Dtsch Arztebl Int"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.cnur.2015.07.012","article-title":"Heart failure: pathophysiology, diagnosis, medical treatment guidelines, and nursing management","volume":"50","author":"Rogers","year":"2015","unstructured":"Rogers C and Bush N. Heart failure: pathophysiology, diagnosis, medical treatment guidelines, and nursing management. Nurs Clin North Am 2015; 50: 787-99.","journal-title":"Nurs Clin North Am"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"106035","DOI":"10.1016\/j.phrs.2021.106035","article-title":"Current and future therapeutic perspective in chronic heart failure","volume":"175","author":"Mascolo","year":"2022","unstructured":"Mascolo A, di Mauro G, Cappetta D, De Angelis A, Torella D, Urbanek K, Berrino L, Nicoletti GF, Capuano A and Rossi F. Current and future therapeutic perspective in chronic heart failure. Pharmacol Res 2022; 175: 106035.","journal-title":"Pharmacol Res"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Athyros VG, Mikhailidis DP, Kakafika AI, Tziomalos K and Karagiannis A. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? Expert Opin Pharmacother 2007; 8: 529-35.","DOI":"10.1517\/14656566.8.5.529"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ejheart.2004.04.013","article-title":"The clinical implications of aldosterone escape in congestive heart failure","volume":"6","author":"Struthers","year":"2004","unstructured":"Struthers AD. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail 2004; 6: 539-45.","journal-title":"Eur J Heart Fail"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2147\/DDDT.S393480","article-title":"Research progress on the efficacy and safety of spironolactone in reversing left ventricular hypertrophy in hemodialysis patients","volume":"17","author":"Sun","year":"2023","unstructured":"Sun Z, Chen Z, Liu R, Lu G, Li Z and Sun Y. Research progress on the efficacy and safety of spironolactone in reversing left ventricular hypertrophy in hemodialysis patients. Drug Des Devel Ther 2023; 17: 181-190.","journal-title":"Drug Des Devel Ther"},{"key":"ref10","unstructured":"Mantero F and Lucarelli G. Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol (Paris) 2000; 61: 52-60."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"105573","DOI":"10.1016\/j.phrs.2021.105573","article-title":"Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: a systematic review and network meta-analysis of randomized clinical trials","volume":"169","author":"Bao","year":"2021","unstructured":"Bao J, Kan R, Chen J, Xuan H, Wang C, Li D and Xu T. Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: a systematic review and network meta-analysis of randomized clinical trials. Pharmacol Res 2021; 169: 105573.","journal-title":"Pharmacol Res"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Leopold JA. Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling. Circulation 2011; 124: e466-8.","DOI":"10.1161\/CIRCULATIONAHA.111.067918"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cardfail.2005.08.002","article-title":"Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction","volume":"12","author":"Wagner","year":"2006","unstructured":"Wagner DR, Delagardelle C, Ernens I, Rouy D, Vaillant M and Beissel J. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J Card Fail 2006; 12: 66-72.","journal-title":"J Card Fail"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.2147\/DDDT.S254948","article-title":"Effects of high-dose rosuvastatin on ventricular remodelling and cardiac function in ST-segment elevation myocardial infarction","volume":"14","author":"Luo","year":"2020","unstructured":"Luo R, Sun X, Shen F, Hong B and Wang Z. Effects of high-dose rosuvastatin on ventricular remodelling and cardiac function in ST-segment elevation myocardial infarction. Drug Des Devel Ther 2020; 14: 3891-3898.","journal-title":"Drug Des Devel Ther"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Authors\/Task Force Members, McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F and Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022; 24: 4-131.","DOI":"10.1002\/ejhf.2333"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/ehjqcco\/qcx031","article-title":"New York Heart Association (NYHA) classification in adults with congenital heart disease: relation to objective measures of exercise and outcome","volume":"4","author":"Bredy","year":"2018","unstructured":"Bredy C, Ministeri M, Kempny A, Alonso-Gonzalez R, Swan L, Uebing A, Diller GP, Gatzoulis MA and Dimopoulos K. New York Heart Association (NYHA) classification in adults with congenital heart disease: relation to objective measures of exercise and outcome. Eur Heart J Qual Care Clin Outcomes 2018; 4: 51-58.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1753944719870084","DOI":"10.1177\/1753944719870084","article-title":"6-minute walking test: a useful tool in the management of heart failure patients","volume":"13","author":"Giannitsi","year":"2019","unstructured":"Giannitsi S, Bougiakli M, Bechlioulis A, Kotsia A, Michalis LK and Naka KK. 6-minute walking test: a useful tool in the management of heart failure patients. Ther Adv Cardiovasc Dis 2019; 13: 1753944719870084.","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/ejhf.1380","article-title":"Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study","volume":"21","author":"Ferreira","year":"2019","unstructured":"Ferreira JP, Metra M, Anker SD, Dickstein K, Lang CC, Ng L, Samani NJ, Cleland JG, van Veldhuisen DJ, Voors AA and Zannad F. Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study. Eur J Heart Fail 2019; 21: 218-226.","journal-title":"Eur J Heart Fail"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Martin N, Manoharan K, Davies C and Lumbers RT. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database Syst Rev 2021; 5: CD012721.","DOI":"10.1002\/14651858.CD012721.pub3"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s11906-000-0027-x","article-title":"Spironolactone in congestive heart failure","volume":"2","author":"Soberman","year":"2000","unstructured":"Soberman JE and Weber KT. Spironolactone in congestive heart failure. Curr Hypertens Rep 2000; 2: 451-6.","journal-title":"Curr Hypertens Rep"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10741-019-09832-y","article-title":"Relative efficacy of spironolactone, eplerenone, and cAnRenone in patients with chronic heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials","volume":"25","author":"Frankenstein","year":"2020","unstructured":"Frankenstein L, Seide S, Täger T, Jensen K, Fröhlich H, Clark AL, Seiz M, Katus HA, Nee P, Uhlmann L, Naci H and Atar D. Relative efficacy of spironolactone, eplerenone, and cAnRenone in patients with chronic heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials. Heart Fail Rev 2020; 25: 161-171.","journal-title":"Heart Fail Rev"},{"key":"ref22","unstructured":"Boccanelli A. Antialdosteronic therapy in mild chronic heart failure: from AREA IN-CHF to EMPHASIS-HF. Recenti Prog Med 2010; 101: 402-405."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1084442","DOI":"10.3389\/fphar.2023.1084442","article-title":"Association between dosing of spironolactone and outcomes in heart failure with preserved ejection fraction patients combined with chronic kidney disease------Balance of efficacy and risk","volume":"14","author":"JF","year":"2023","unstructured":"Li JF, Qu X, Gao Z, Chen CX, Zhang FY, Cheng L, Zhou X and Zhou H. Association between dosing of spironolactone and outcomes in heart failure with preserved ejection fraction patients combined with chronic kidney disease------Balance of efficacy and risk. Front Pharmacol 2023; 14: 1084442.","journal-title":"Front Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Tao P, Zhitao T and Jiming L. A retrospective study on the short-term effect of high-dose spironolactone (80 mg\/d) on chronic congestive heart failure. Medicine (Baltimore) 2021; 100: e23188.","DOI":"10.1097\/MD.0000000000023188"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/nep.12188","article-title":"The role of albuminuria as a non-invasive marker for congestive acutely decompensated chronic heart failure and the spironolactone effect in elderly Portuguese: a non-randomized trial","volume":"19","author":"Ferreira","year":"2014","unstructured":"Ferreira JP, Santos M, Almeida S, Marques I, Bettencourt P and Carvalho H. The role of albuminuria as a non-invasive marker for congestive acutely decompensated chronic heart failure and the spironolactone effect in elderly Portuguese: a non-randomized trial. Nephrology (Carlton) 2014; 19: 149-56.","journal-title":"Nephrology (Carlton)"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccl.2013.09.002","article-title":"The renin-angiotensin-aldosterone system and heart failure","volume":"32","author":"Sayer","year":"2014","unstructured":"Sayer G and Bhat G. The renin-angiotensin-aldosterone system and heart failure. Cardiol Clin 2014; 32: 21-32.","journal-title":"Cardiol Clin"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Follath F. Challenging the dogma of high target doses in the treatment of heart failure: is more always better? Arch Cardiovasc Dis 2009; 102: 785-9.","DOI":"10.1016\/j.acvd.2009.08.011"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.cardiores.2005.12.002","article-title":"Structure and function of matrix metalloproteinases and TIMPs","volume":"69","author":"Nagase","year":"2006","unstructured":"Nagase H, Visse R and Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-73.","journal-title":"Cardiovasc Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIRCRESAHA.114.303634","article-title":"Targeted overexpression of tissue inhibitor of matrix metalloproteinase-4 modifies post-myocardial infarction remodeling in mice","volume":"114","author":"Zavadzkas","year":"2014","unstructured":"Zavadzkas JA, Stroud RE, Bouges S, Mukherjee R, Jones JR, Patel RK, McDermott PJ and Spinale FG. Targeted overexpression of tissue inhibitor of matrix metalloproteinase-4 modifies post-myocardial infarction remodeling in mice. Circ Res 2014; 114: 1435-45.","journal-title":"Circ Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1152\/physrev.00012.2007","article-title":"Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function","volume":"87","author":"Spinale","year":"2007","unstructured":"Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007; 87: 1285-342.","journal-title":"Physiol Rev"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2217\/bmm.15.121","article-title":"Using the galectin-3 test to predict mortality in heart failure patients: a systematic review and meta-analysis","volume":"10","author":"Chen","year":"2016","unstructured":"Chen YS, Gi WT, Liao TY, Lee MT, Lee SH, Hsu WT, Chang SS and Lee CC. Using the galectin-3 test to predict mortality in heart failure patients: a systematic review and meta-analysis. Biomark Med 2016; 10: 329-42.","journal-title":"Biomark Med"},{"key":"ref32","unstructured":"van Kimmenade RR, Bakker JA, Crijns HJ, van Dieijen-Visser MP and Pinto YM. The value of (NT-pro) BNP in the diagnosis, prognosis and treatment of congestive heart failure. Neth Heart J 2004; 12: 61-63."}],"container-title":["American Journal of Cardiovascular Disease"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcd\/14\/1\/ajcd0154265.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:52:51Z","timestamp":1766022771000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcd\/14\/1\/ajcd0154265.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/syix9692","relation":{},"ISSN":["2160-200X"],"issn-type":[{"type":"electronic","value":"2160-200X"}],"subject":[],"published":{"date-parts":[[2024]]}}}